GRI

Marstacimab approved to treat patients aged 12 years and above (weighing at least 35 kg) with haemophilia A or B

News Healthcare & Pharma Law & Policy Updates
Date: 22nd Apr, 2025 Source: Medicines and Healthcare products Regulatory Agency (MHRA) Country: United Kingdom Original Source

Brief

"On 22/04/2025, the Medicines and Healthcare products Regulatory Agency (MHRA) issued an update regarding Marstacimab approved to treat patients aged 12 years and above (weighing at least 35 kg) with haemophilia A or B. This approval marks a significant milestone in the treatment of bleeding disorders, offering a new option for patients with severe haemophilia A and B."

This content is restricted.

Highlights content goes here...

This content is restricted.

Medicines and Healthcare products Regulatory Agency (MHRA)

Quick Insight
RADA.AI
RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested
Related Documents
32 million euros for patent calls+, drawings+ and brands+ from 2025
Date: 2nd Sep, 2025 Source: Italian Patent and Trademark Office Country: Italy
News Intellectual property Law & Policy Updates
Increased risks identified with Profemur cobalt chrome modular neck hip replacements
Date: 4th Sep, 2025 Source: Medicines and Healthcare products Regulatory Agency (MHRA) Country: United Kingdom
News Healthcare & Pharma Guidance
CFTC Issues Policy Statement on Referrals for Potential Criminal Enforcement
Date: 5th Sep, 2025 Source: Commodity Futures Trading Commission (CFTC) Country: USA
News Corporate Finance & M&A Law & Policy Updates

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Click here

Enter your Email

Enter your registered username/email id.

Enter your Email

Enter your email id below to signup.
Individual Plan
  • Designed for Growing Compliance Teams
$125 / month OR $1250 / year
Features
  • • Coverage for 20 jurisdictions
  • • Monitoring from 500+ regulatory authorities
  • • AI compliance summaries
  • • RaDa.ai : Single-Role
Best for: Researchers, Legal professionals, Academics
Subscribe Now
Enterprise Plan
  • Perfect for Global Enterprises
Contact for Pricing
Features
  • • Custom jurisdictional coverage
  • • Custom monitoring of regulatory authorities
  • • RaDa.ai : Customizable multi-role
  • • Custom reporting and dashboard capabilities
  • • API access for seamless integration
Best for: Law Firms, Corporations, Government Bodies
Contact Sales